Publication | Closed Access

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Breast OncologyOncologyLba15 Primary ResultsPathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentFirst-line PaclitaxelMedicineRadiation OncologyMolecular Oncology